There is now increasing evidence that neuronal damage in the-age-related neurodegenerative diseases is mediated by the mechanism of oxidative stress. Oxidative stress occurs when there is an overproduction of reactive oxygen species (ROS), an underactivity of cellular defense mechanisms, or both, leading to uncontrolled oxidation of critical biological molecules. The products of such oxidative attack on macromolecules include the formation of lipid hydroperoxides and aldehyde breakdown products, nitrotyrosine and carbonyl modifications of proteins, and DNA hydroxylation. Amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam displays many similarities to the age-related neurodegenerative diseases but with an earlier onset and much higher prevalence suggesting that ALS/PDC recapitulates the pathogenetic mechanism(s) of the age-related neurodegenerative diseases at an intense level. We have developed evidence of oxidative damage in ALS/PDC and the neurodegenerative diseases of aging, suggesting that the mechanism of oxidative stress participates in producing neuronal degeneration. In both ALS/PDC and Alzheimer's disease we have shown evidence of nitrated tyrosine residues localized to neurofibrillary tangles of the hippocampus and entorhinal cortex, and in both ALS/PDC and idiopathic Parkinson's disease we have demonstrated increased iron concentrations within dopaminergic neurons of the substantia nigra. In this project, we will further examine cases of ALS/PDC for evidence of oxidative damage. The end products of oxidative damage to cellular structures that we will investigate include lipid peroxidation (malondialdehyde), protein nitration (nitrotyrosine), protein oxidation (protein carbonyls) and DNA hydroxylation (8-OlI-dG). We will also investigate the potential for oxidative stress to develop as a result of increased intraneuronal iron, decreased ferritin or a decrease in glutathione content. Low molecular weight iron, unprotected by storage in ferritin, can mediate the oxidation of macromolecules initiating lipid peroxidation, DNA hydroxylation or site specific protein oxidation. Protection against an increase in available iron, and therefore the production of ROS, is accomplished by increasing iron storage capacity in response to increases in intracellular free iron. Glutathione, the major defense against ROS produced in the brain, is oxidised by glutathione peroxidase reducing hydrogen peroxide to water. A decline of cellular glutathione content, implicated in Parkinson's disease, will cause a decrease in the removal of hydrogen peroxide and an increase in the potential for the generation of hydroxyl radicals.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG014382-03
Application #
6295651
Study Section
Project Start
1999-03-01
Project End
2000-02-29
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Dombroski, Beth A; Galasko, Douglas R; Mata, Ignacio F et al. (2013) C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. JAMA Neurol 70:742-5
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Lee, Virginia M-Y; Brunden, Kurt R; Hutton, Michael et al. (2011) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 1:a006437
Yu, Chang-En; Bird, Thomas D; Bekris, Lynn M et al. (2010) The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol 67:161-70
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Snyder, L R; Cruz-Aguado, R; Sadilek, M et al. (2009) Lack of cerebral bmaa in human cerebral cortex. Neurology 72:1360-1
Choi, Yoonha; Wijsman, Ellen M; Weir, Bruce S (2009) Case-control association testing in the presence of unknown relationships. Genet Epidemiol 33:668-78
Sieh, Weiva; Choi, Yoonha; Chapman, Nicola H et al. (2009) Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Hum Mol Genet 18:3725-38

Showing the most recent 10 out of 53 publications